MedTrace Logo

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT01368588 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2590

Last updated 2026-05-08

Study results available
· View outcomes & findings →

Summary

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.

PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.

Conditions

Interventions

RADIATION

three-dimensional conformal radiotherapy

Daily fractions

RADIATION

intensity modulated radiotherapy

Daily fractions

RADIATION

Brachytherapy

Implant

DRUG

Anti-androgen

Tablet

DRUG

luteinizing hormone-releasing hormone (LHRH) agonist or antagonist

Injection

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • NRG Oncology

    collaborator OTHER

  • Radiation Therapy Oncology Group

    lead NETWORK

Principal Investigators

  • Mack Roach, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2025-04-17
Completion
2031-07-31

Countries

  • United States
  • Canada
  • Hong Kong
  • Israel
  • Singapore
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01368588 on ClinicalTrials.gov